Evidence map›Paper›PMID 36136061›Full record

ArticleCancer science2023

Nucleic acid-triggered tumoral immunity propagates pH-selective therapeutic antibodies through tumor-driven epitope spreading.

Genta Furuya, Hiroto Katoh, Shinichiro Atsumi, Itaru Hashimoto, Daisuke Komura, Ryo Hatanaka, Shogo Senga, Shuto Hayashi, Shoji Akita, Hirofumi Matsumura and 18 more

Open access · goldAbstract read
In one paragraph

Article in Cancer science, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors at 7 institutions in 2 countries.

Genta FuruyaDepartment of Preventive medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Hiroto KatohDepartment of Preventive medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.ORCID https://orcid.org/0000-0001-9440-728X
Shinichiro AtsumiDepartment of Preventive medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Itaru HashimotoDepartment of Preventive medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Daisuke KomuraDepartment of Preventive medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.ORCID https://orcid.org/0000-0002-0038-728X
Ryo HatanakaDiscovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd., Ibaraki, Japan.
Shogo SengaDiscovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd., Ibaraki, Japan.
Shuto HayashiDepartment of Preventive medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Shoji AkitaDiscovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd., Ibaraki, Japan.
Hirofumi MatsumuraDiscovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd., Ibaraki, Japan.
Akihiro MiuraDiscovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd., Ibaraki, Japan.
Hideaki MitaDepartment of Preventive medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Makoto NakakidoLaboratory of Medical Proteomics, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Satoru NagatoishiLaboratory of Medical Proteomics, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Akira SugiyamaLaboratory of Systems Biology and Medicine, Research Center for Advanced Science and Technology, The University of Tokyo, Tokyo, Japan.ORCID https://orcid.org/0000-0003-4406-9475
Ryohei SuzukiDepartment of Preventive medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Hiroki KonishiDepartment of Preventive medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Asami YamamotoDepartment of Preventive medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Hiroyuki AbeDepartment of Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Nobuyoshi HiraokaDepartment of Analytical Pathology, National Cancer Center Research Institute, Tokyo, Japan.ORCID https://orcid.org/0000-0003-4215-4385
Kazunori AokiDivision of Molecular and Cellular Medicine, National Cancer Center Research Institute, Tokyo, Japan.ORCID https://orcid.org/0000-0002-1292-3764
Yasumasa KatoDepartment of Oral Function and Molecular Biology, Ohu University School of Dentistry, Fukushima, Japan.
Yasuyuki SetoDepartment of Gastrointestinal Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Chihoko YoshimuraDiscovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd., Ibaraki, Japan.
Kazutaka MiyaderaDiscovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd., Ibaraki, Japan.
Kouhei TsumotoLaboratory of Medical Proteomics, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Tetsuo UshikuDepartment of Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Shumpei IshikawaDepartment of Preventive medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
The University of Tokyo · JPTaiho Pharmaceutical (Japan) · JPTokyo Medical University · JPNational Cancer Research Institute · GBOhu University · JPTokyo University of Science · JPUniversity of Tokyo Hospital · JP

Funding

Japan Agency for Medical Research and Development JP22ak0101096Japan Agency for Medical Research and Development JP22am0401010Japan Society for the Promotion of Science 19H01032Mizutani Foundation for GlycoscienceTaiho Pharmaceutical
6 · The paper itself

Abstract

Important roles of humoral tumor immunity are often pointed out; however, precise profiles of dominant antigens and developmental mechanisms remain elusive. We systematically investigated the humoral antigens of dominant intratumor immunoglobulin clones found in human cancers. We found that approximately half of the corresponding antigens were restricted to strongly and densely negatively charged polymers, resulting in simultaneous reactivities of the antibodies to both densely sulfated glycosaminoglycans (dsGAGs) and nucleic acids (NAs). These anti-dsGAG/NA antibodies matured and expanded via intratumoral immunological driving force of innate immunity via NAs. These human cancer-derived antibodies exhibited acidic pH-selective affinity across both antigens and showed specific reactivity to diverse spectrums of human tumor cells. The antibody-drug conjugate exerted therapeutic effects against multiple cancers in vivo by targeting cell surface dsGAG antigens. This study reveals that intratumoral immunological reactions propagate tumor-oriented immunoglobulin clones and demonstrates a new therapeutic modality for the universal treatment of human malignancies.

Indexed as

NeoplasmsNucleic AcidsAntibodiesAntigensAntigens, SurfaceEpitopesHumansHydrogen-Ion ConcentrationAntibodiesAntigensAntigens, SurfaceEpitopesNucleic Acids(14) characteristics and pathology of human cancerhumoral immunityimmune repertoirepH-selective antibodysulfated glycosaminoglycantumor-infiltrating B cell

Identifiers

PMID36136061
PMCPMC9807517
OpenAlexW4296683467

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.